An experienced and accomplished healthcare leader has been appointed Chief Executive of Myeloma UK. Rosemarie Finley is joining Myeloma UK […]
The National Institute for Health and Care Excellence (NICE) has approved carfilzomib (Kyprolis®) in combination with dexamethasone for use on […]
Alcentra CEO and philanthropist David Forbes-Nixon has donated £1 million over 5 years to Myeloma UK through the DFN Charitable […]
Researchers have published an article outlining that the Cancer Drugs Fund (CDF), a Government policy designed to provide access to […]
The National Institute for Health and Care Excellence (NICE) has issued a draft “no” on ixazomib (Ninlaro®) for the treatment of patients with relapsed or refractory […]
The National Institute for Health and Care Excellence (NICE) has today published draft negative guidance on daratumumab (Darzalex®) monotherapy used […]
Cancer charity Myeloma UK, has launched MUK eleven, a first of its kind immunotherapy trial which aims to modulate the immune system to target myeloma. The Phase 1b trial will study oncolytic virus, Reolysin® (pelareorep), in combination with immunomodulatory drugs (IMiDs) as a rescue treatment in relapsing myeloma patients.
Myeloma UK has expressed disappointment at news that proposals to introduce a £20m budget impact test for new medicines approved […]
Myeloma UK Policy and Public Affairs Manager Kate Morgan commented, “Myeloma UK made a strong case to the Scottish Medicines Consortium for the approval of both indications and we are very disappointed by the decision not to recommend them for use.
After 20 years of outstanding service, Eric Low has announced that he is moving on from his post as Chief […]